Balancing market value and patient populations - autoimmune treatments in emerging markets

The large new patient pool in emerging markets indicates huge potential for the life sciences industry in autoimmune diseases but a new report from Datamonitor* suggests that it may be too soon to generate substantial market value outside the major markets.

Autoimmune diseases offer a growth opportunity for pharmaceutical companies, with patients requiring long-term treatment, often with novel, expensive biologics. In a time when breaking even in other areas feels like a success, growing sales and burgeoning pipelines in autoimmune diseases across the major markets show why the industry is turning its focus to autoimmune treatments.